142 results on '"Ravandi F"'
Search Results
2. P369: A PHASE II STUDY OF MINI-HYPER-CVD PLUS VENETOCLAX IN PATIENTS WITH PHILADELPHIA CHROMOSOME-NEGATIVE ACUTE LYMPHOBLASTIC LEUKEMIA
3. P520: PHASE 1/2 STUDY OF SEL24/MEN1703, A FIRST-IN-CLASS DUAL PIM/FLT3 KINASE INHIBITOR, IN PATIENTS WITH IDH1/2-MUTATED ACUTE MYELOID LEUKEMIA: THE DIAMOND-01 TRIAL.
4. P770: A COMPARATIVE STUDY OF LEUKEMIC TRANSFORMATION IN THERAPY-RELATED AND DE NOVO MYELODYSPLASTIC SYNDROME AFTER HYPOMETHYLATING AGENT FAILURE
5. P497: PROGNOSTIC IMPACT OF RAS AND C-KIT MUTATIONS (SINGLE VS. MULTIPLE) IN CORE-BINDING FACTOR ACUTE MYELOID LEUKEMIA TREATED WITH FLUDARABINE, CYTARABINE, G-CSF (FLAG) BASED REGIMEN
6. P760: PATTERNS OF HYPOMETHYLATING AGENT FAILURE IN PATIENTS WITH MYELODYSPLASTIC SYNDROMES
7. P757: RESULTS OF A PHASE 1 STUDY OF AZACITIDINE COMBINED WITH VENETOCLAX FOR TREATMENT-NAIVE AND RELAPSED HIGH-RISK MYELODYSPLASTIC SYNDROME AND CHRONIC MYELOMONOCYTIC LEUKEMIA
8. P695: PROGNOSTIC IMPACT OF ASXL1 MUTATIONS IN CHRONIC PHASE CML
9. P1194: A PHASE IB TRIAL OF ITACITINIB COMBINED WITH ALEMTUZUMAB IN PATIENTS WITH T-CELL PROLYMPHOCYTIC LEUKEMIA (T-PLL)
10. P355: MINI-HYPER-CVD PLUS INOTUZUMAB OZOGAMICIN, WITH OR WITHOUT BLINATUMOMAB, IN OLDER ADULTS WITH NEWLY DIAGNOSED B-CELL ACUTE LYMPHOBLASTIC LEUKEMIA: UPDATES FROM A PHASE II TRIAL
11. P581: PHASE II STUDY OF LOWER-INTENSITY FRONTLINE THERAPY FOR NEWLY DIAGNOSED PATIENTS WITH AML WHO ARE UNFIT OR OTHERWISE NOT ELIGIBLE FOR FRONTLINE CLINICAL TRIALS
12. P541: OUTCOMES AND MANAGEMENT OF PATIENTS WITH NEWLY DIAGNOSED ACUTE MYELOID LEUKEMIA PRESENTING WITH HYPERLEUKOCYTOSIS
13. P498: CLINICAL AND BIOLOGICAL MARKERS ASSOCIATED WITH LONG-TERM SURVIVAL FOR PATIENTS WITH ACUTE MYELOID LEUKEMIA (AML) IN REMISSION AFTER CHEMOTHERAPY IN THE QUAZAR AML-001 TRIAL OF ORAL AZACITIDINE
14. P576: A PHASE I/II STUDY OF MILADEMETAN (DS3032B) IN COMBINATION WITH LOW DOSE CYTARABINE WITH OR WITHOUT VENETOCLAX IN ACUTE MYELOID LEUKEMIA
15. P495: PHASE 2 STUDY OF ASTX727 (DECITABINE/CEDAZURIDINE) PLUS VENETOCLAX IN PATIENTS WITH RELAPSED/REFRACTORY ACUTE MYELOID LEUKEMIA (AML) OR PREVIOUSLY UNTREATED, ELDERLY PATIENTS UNFIT FOR CHEMOTHERAPY
16. P566: IMPACT OF FRONTLINE INDUCTION APPROACH ON POST-STEM CELL TRANSPLANT (SCT) OUTCOMES IN OLDER ADULTS WITH NEWLY DIAGNOSED ACUTE MYELOID LEUKEMIA (AML)
17. P367: LONG TERM OUTCOMES OF NEWLY DIAGNOSED CRLF2 REARRANGED B-CELL ACUTE LYMPHOBLASTIC LEUKEMIA
18. PB1831: UTILITY OF FLT3 INHIBITORS IN PATIENTS WITH ACUTE MYELOID LEUKEMIA (AML) AND T(6;9)(P22;Q34)
19. P506: ACHIEVEMENT OF MEASURABLE RESIDUAL DISEASE CLEARANCE IS A STRONGER PREDICTOR OF PATIENT OUTCOME THAN TREATMENT INTENSITY IN NEWLY DIAGNOSED PATIENTS WITH ACUTE MYELOID LEUKEMIA
20. P499: THE PHASE 1B OMNIVERSE TRIAL OF ORAL AZACITIDINE IN COMBINATION WITH VENETOCLAX FOR TREATMENT OF RELAPSED/REFRACTORY OR NEWLY DIAGNOSED ACUTE MYELOID LEUKEMIA (TRIAL IN PROGRESS)
21. P368: A PHASE II STUDY OF INOTUZUMAB OZOGAMICIN FOR THE TREATMENT OF MEASURABLE RESIDUAL DISEASE-POSITIVE B-CELL ACUTE LYMPHOBLASTIC LEUKEMIA
22. P703: ASSOCIATION BETWEEN BARIATRIC SURGERY AND OUTCOMES IN PATIENTS WITH CHRONIC MYELOID LEUKEMIA TREATED WITH ORAL TYROSINE KINASE INHIBITORS
23. P365: INCORPORATION OF NELARABINE (NEL), PEGYLATED ASPARAGINASE (PEG) AND VENETOCLAX (VEN) IN THE FRONTLINE THERAPY OF ADULT PATIENTS WITH T-ACUTE LYMPHOBLASTIC LEUKEMIA/T-LYMPHOBLASTIC LYMPHOMA (T-ALL/LBL)
24. S114: PONATINIB AND BLINATUMOMAB FOR PATIENTS WITH PHILADELPHIA CHROMOSOME-POSITIVE ACUTE LYMPHOBLASTIC LEUKEMIA: UPDATED RESULTS FROM A PHASE II STUDY
25. P496: CLINICAL CHARACTERISTICS OF SECONDARY MYELOID NEOPLASMS IN PATIENTS WITH INFLAMMATORY BOWEL DISEASE
26. P575: IMPACT OF MOLECULAR RESPONSE AND CHEMOTHERAPY REGIMEN ON OUTCOMES IN CORE BINDING FACTOR AML
27. P371: HYPER-CVAD WITH SEQUENTIAL BLINATUMOMAB, WITH OR WITHOUT INOTUZUMAB OZOGAMICIN, IN ADULTS WITH NEWLY DIAGNOSED PHILADELPHIA CHROMOSOME-NEGATIVE B-CELL ACUTE LYMPHOBLASTIC LEUKEMIA
28. S1614 CHROMOSOMAL ABNORMALITIES DETERMINE OUTCOME IN NPM1MUT/FLT3-ITDNEG/LOW ACUTE MYELOID LEUKEMIA
29. S1615 SAFETY, EFFICACY, AND BIOMARKERS OF RESPONSE TO AZACITIDINE (AZA) WITH NIVOLUMAB (NIVO) AND IPILIMUMAB (IPI), AND AZA WITH NIVO IN R/R ACUTE MYELOID LEUKEMIA: A NON-RANDOMIZED, PHASE 2 STUDY.
30. PB1722 IMPACT OF CD33 AND ABCB1 SINGLE NUCLEOTIDE POLYMORPHISMS IN PATIENTS WITH ACUTE MYELOID LEUKEMIA AND HIGH-RISK MYELODYSPLASTIC SYNDROMES TREATED WITH DECITABINE PLUS GEMTUZUMAB OZOGAMICIN
31. PF281 CLI24–001: FIRST IN HUMAN STUDY OF SEL24/MEN1703, AN ORAL DUAL PIM/FLT3 KINASE INHIBITOR, IN PATIENTS WITH ACUTE MYELOID LEUKEMIA
32. PF205 RNA BASED IMMUNE SIGNATURES MAY PREDICT RESPONSES TO PD-1 INHIBITION AND AZACITIDINE TREATMENT IN ACUTE MYELOID LEUKEMIA (AML): A SUBSET ANALYSIS OF A PHASE 2 STUDY
33. S833 THE SINGLE-CELL ATLAS OF DRIVER MUTATIONS IN AML
34. PF212 NEXT-GENERATION SEQUENCING OF CIRCULATING CELL-FREE DNA PROVIDES COMPLEMENTARY INFORMATION TO GENOMIC PROFILING OF BONE MARROW IN PATIENTS WITH ACUTE LEUKEMIAS
35. PS1037 FINAL REPORT: CLINICAL STUDY OF ORAL ARSENIC TRIOXIDE CAPSULE FORMULATION, ORH-2014, DEMONSTRATING HIGH BIOAVAILABILITY, GOOD SAFETY AND TOLERABILITY IN PATIENTS WITH ADVANCED HEMATOLOGIC DISORDERS
36. PF673 PHASE 1/2 STUDY OF RUXOLITINIB (RUX) PLUS DECITABINE (DAC) IN PATIENTS (PTS) WITH POST-MYELOPROLIFERATIVE NEOPLASM ACUTE MYELOID LEUKEMIA (POST-MPN AML)
37. PS1064 EXPLORATORY ANALYSIS OF OUTCOMES WITH SEQUENTIAL FLT3-INHIBITOR (FLT3I) BASED THERAPIES IN RELAPSED FLT3-MUTATED AML PATIENTS (PTS)
38. Achievement of a negative minimal residual disease state after hypomethylating agent therapy in older patients with AML reduces the risk of relapse
39. Influence of IDH on FLT3-ITD status in newly diagnosed AML
40. Characteristics, outcomes, prognostic factors and treatment of patients with T-cell prolymphocytic leukemia (T-PLL)
41. Updated Results from Phase 2 Study of Guadecitabine for Patients with Untreated INT-2/High Risk Myelodysplastic Syndromes or Chronic Myelomonocytic Leukemia
42. Prognostic Impact of Mutations in Patients with Myelodysplastic Syndromes and Myelodysplastic/Myeloproliferative Neoplasms with Normal Karyotype
43. Persistence of Preleukemic Clonal Hematopoiesis after Chemotherapy is Associated with Poor Prognosis in Patients with High Risk MDS and AML
44. Impact of the Type of First-Cancer Therapy in Therapy-Related Myelodysplastic Syndromes Outcomes
45. Erratum: A clinical trial for patients with acute myeloid leukemia or myelodysplastic syndromes not eligible for standard clinical trials
46. A CpG island methylator phenotype in acute myeloid leukemia independent of IDH mutations and associated with a favorable outcome
47. A clinical trial for patients with acute myeloid leukemia or myelodysplastic syndromes not eligible for standard clinical trials
48. Frontline therapy with high-dose imatinib versus second generation tyrosine kinase inhibitor in patients with chronic-phase chronic myeloid leukemia - a propensity score analysis
49. New drugs in acute myeloid leukemia
50. Clinical, pharmacokinetic and pharmacodynamic data for the MEK1/2 inhibitor pimasertib in patients with advanced hematologic malignancies
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.